Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefdinir

FDA-approved product (capsule, oral), marketed as Cefdinir, Omnicef.

Registered studies
32
Lab records
8
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cefdinir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Infection
  • Infectious otitis media
  • Otitis media
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
FDA pharmacologic class
Cephalosporin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD15; FDA class Cephalosporin Antibacterial

Repurposing investigation

Cefdinir is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 2 of 2 lab records
Open Cefdinir in ChEMBL Registered studies below
Show the 8 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefdinir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cefdinir Capsules 300 mg, Non-fasting

    NCT00834535 · start 2005-07

    Registered record
    Registry ID
    NCT00834535
    Conditions
    Healthy
    Interventions
    Cefdinir Capsules 300 mg; OMNICEF® Capsule 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2005-08
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir Capsules 300 mg; OMNICEF® Capsule 300 mg
    PhasePhase 1
    Registry statusCompleted

  • Cefdinir Capsules 300 mg, Fasting

    NCT00835484 · start 2005-07

    Registered record
    Registry ID
    NCT00835484
    Conditions
    Healthy
    Interventions
    Cefdinir Capsules 300 mg; OMNICEF® 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2005-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir Capsules 300 mg; OMNICEF® 300 mg
    PhasePhase 1
    Registry statusCompleted

  • To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions

    NCT00882154 · start 2005-04

    Registered record
    Registry ID
    NCT00882154
    Conditions
    Healthy
    Interventions
    Cefdinir 300 mg Capsule (Sandoz, Austria); Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir 300 mg Capsule (Sandoz, Austria); Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
    PhasePhase 1
    Registry statusCompleted

  • To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions

    NCT00882570 · start 2005-04

    Registered record
    Registry ID
    NCT00882570
    Conditions
    Healthy
    Interventions
    Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria); Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria); Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
    PhasePhase 1
    Registry statusCompleted

  • To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions

    NCT00882700 · start 2005-04

    Registered record
    Registry ID
    NCT00882700
    Conditions
    Healthy
    Interventions
    Cefdinir 300 mg Capsule (Sandoz, Austria); Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir 300 mg Capsule (Sandoz, Austria); Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
    PhasePhase 1
    Registry statusCompleted

  • To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions

    NCT00883883 · start 2005-04

    Registered record
    Registry ID
    NCT00883883
    Conditions
    Healthy
    Interventions
    Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria); Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir 250 mg/5 ml Suspension (Sandoz, Austria); Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections

    NCT00234949 · start 2005-03

    Registered record
    Registry ID
    NCT00234949
    Conditions
    Mild to Moderate Uncomplicated Skin and Skin Structure Infections
    Interventions
    cefdinir; cephalexin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-03
    Completion
    Not recorded
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild to Moderate Uncomplicated Skin and Skin Structure Infections
    Interventioncefdinir; cephalexin
    PhasePhase 4
    Registry statusCompleted

  • Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting

    NCT00835549 · start 2005-03

    Registered record
    Registry ID
    NCT00835549
    Conditions
    Healthy
    Interventions
    Cefdinir for oral suspension 250 mg/5mL; OMNICEF® for oral suspension 250 mg/5mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-03
    Completion
    2005-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir for oral suspension 250 mg/5mL; OMNICEF® for oral suspension 250 mg/5mL
    PhasePhase 1
    Registry statusCompleted

  • Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life

    NCT00147914 · start 2005-02

    Registered record
    Registry ID
    NCT00147914
    Conditions
    Acute Bacterial Sinusitis
    Interventions
    Cefdinir (drug); amoxicillin/clavulanate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-02
    Completion
    2017-02-18
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Sinusitis
    InterventionCefdinir (drug); amoxicillin/clavulanate
    PhasePhase 4
    Registry statusCompleted

  • Cefdinir for Oral Suspension 250 mg/5mL, Fasting

    NCT00834574 · start 2005-02

    Registered record
    Registry ID
    NCT00834574
    Conditions
    Healthy
    Interventions
    Cefdinir for oral suspension 250 mg/5mL; OMNICEF® for oral suspension 250 mg/5mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-02
    Completion
    2005-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCefdinir for oral suspension 250 mg/5mL; OMNICEF® for oral suspension 250 mg/5mL
    PhasePhase 1
    Registry statusCompleted

  • Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

    NCT00645073 · start 2003-11

    Registered record
    Registry ID
    NCT00645073
    Conditions
    Acute Bacterial Sinusitis
    Interventions
    cefdinir (Omnicef); levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    Not recorded
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Sinusitis
    Interventioncefdinir (Omnicef); levofloxacin
    PhasePhase 4
    Registry statusCompleted

  • A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media

    NCT00645112 · start 2003-11

    Registered record
    Registry ID
    NCT00645112
    Conditions
    Acute Otitis Media
    Interventions
    cefdinir (Omnicef); azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    Not recorded
    Enrolment
    357

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Otitis Media
    Interventioncefdinir (Omnicef); azithromycin
    PhasePhase 4
    Registry statusCompleted

  • A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media

    NCT00644943 · start 2003-02

    Registered record
    Registry ID
    NCT00644943
    Conditions
    Acute Otitis Media
    Interventions
    cefdinir (Omnicef); amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-02
    Completion
    Not recorded
    Enrolment
    425

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Otitis Media
    Interventioncefdinir (Omnicef); amoxicillin
    PhasePhase 4
    Registry statusCompleted

  • A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications

    NCT00644774 · start 2003-01

    Registered record
    Registry ID
    NCT00644774
    Conditions
    Healthy
    Interventions
    cefdinir (Omnicef); azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    Not recorded
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncefdinir (Omnicef); azithromycin
    PhasePhase 4
    Registry statusCompleted

  • Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications

    NCT00644891 · start 2003-01

    Registered record
    Registry ID
    NCT00644891
    Conditions
    Healthy
    Interventions
    cefdinir (Omnicef); amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    Not recorded
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncefdinir (Omnicef); amoxicillin
    PhasePhase 4
    Registry statusCompleted